<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339102</url>
  </required_header>
  <id_info>
    <org_study_id>P17-176</org_study_id>
    <nct_id>NCT03339102</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients</brief_title>
  <official_title>Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for &quot;Re-examination of New Drugs&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of Humira®
      (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis
      patients under a routine treatment practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of patients reported with serious adverse event</measure>
    <time_frame>Up to Week 32</time_frame>
    <description>The patients reported with serious adverse event will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual acuity</measure>
    <time_frame>Up to follow-up week 22</time_frame>
    <description>The change in visual acuity is assessed from the best corrected visual acuity achieved after the first dose on visual acuity chart in each eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Presence /absence of new active inflammatory chorioretinal lesions</measure>
    <time_frame>Up to follow-up week 22</time_frame>
    <description>Presence or absence of new active inflammatory chorioretinal lesions is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Treatment Response</measure>
    <time_frame>Up to follow-up week 22</time_frame>
    <description>Treatment response is assessed as improvement, no improvement and aggravation.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Participants who received Humira®</arm_group_label>
    <description>Non-infectious intermediate, posterior, or panuveitis patients who received Humira®</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Non-infectious intermediate, posterior and panuveitis (NIIPPU) patients who had been
        prescribed with Humira® will be registered to the study in accordance with the drug
        approval status as well as the investigator's clinical judgment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis

          -  Patients voluntarily signed a patient authorization &amp; informed consent form.

          -  Decision on the treatment with Humira® was made prior to any decision to approach the
             patient to participate in this study.

          -  Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC)
             and professional and/or reimbursement guidelines.

        Exclusion Criteria:

          -  A patient who are contraindications to originator adalimumab (Humira®) as listed on
             the approved Korean label.

          -  A patient who is participating on other interventional clinical trials

          -  Prior treatment with Humira®, including current course of Humira® started prior to
             baseline visit assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunjin Kim</last_name>
    <phone>+82 2 3429 9241</phone>
    <email>hkim@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan National University Hosp</name>
      <address>
        <city>Busan</city>
        <state>Busan Gwang Yeogsi</state>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Med Ctr</name>
      <address>
        <city>Daegu</city>
        <state>Daegu Gwang Yeogsi</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National Univ Bundang ho</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggido</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HanGil Eye Hospital</name>
      <address>
        <city>Bupyeong</city>
        <state>Incheon Gwang Yeogsi</state>
        <zip>21388</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryknoll Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>48972</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-infectious intermediate, posterior and panuveitis</keyword>
  <keyword>Post-Marketing Surveillance</keyword>
  <keyword>Humira®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

